Revealing IGLC6: a key molecule discovered in the constant region of immunoglobulin light chains

Target Name: IGLC6

NCBI ID: G3542

Other Name(s): Immunoglobulin lambda constant 6 (Kern+Oz- marker, gene/pseudogene) | immunoglobulin lambda constant 6 | IGLC

Revealing IGLC6: a key molecule discovered in the constant region of immunoglobulin light chains

Summary

IGLC6, immunoglobulin light chain constant region (Immunoglobulin lambda constant 6, KERN+OZ-marker, gene/pseudogene) plays an important role in immunoglobulin production. Variations in IGLC6 are associated with the occurrence of various immune diseases, such as autoimmune diseases, inflammation and tumors. IGLC6 is also associated with the therapeutic effects of some drugs. Therefore, studying the application of IGLC6 in immune diseases has high clinical value.

introduction

Immunoglobulin light chain (Immunoglobulin light chain, mALB) is an important component of the immune system. It is secreted by B cells and is mainly responsible for the formation of antibodies. In humans, mALB is divided into five constant regions, namely constant regions 伪, 尾, 纬, 未, and 蔚. Among them, the constant regions 伪 and 尾 are responsible for the structural stability and functional diversity of the antibody molecule. IGLC6 is an important element in the 伪 subregion of the mALB constant region.

Discovery and research of IGLC6

The discovery of IGLC6 originated from the study of immunoglobulin light chain constant region genes. Because of its unique function in mALB generation, IGLC6 has been intensively studied by scientists. Studies have found that IGLC6 is conserved in the 伪 subregion of the light chain constant region of mALB, and the structure and function of IGLC6 are highly conserved in various species. This lays the foundation for studying the application of IGLC6 in immune diseases.

Further research showed that IGLC6 plays an important role in the production of immunoglobulin light chains. Variations in IGLC6 are associated with the occurrence of various immune diseases, such as autoimmune diseases, inflammation and tumors. For example, studies have found that IGLC6 variants are associated with the occurrence of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, IGLC6 mutations are closely related to inflammation and tumorigenesis.

In addition to being related to the occurrence of diseases, IGLC6 is also related to the therapeutic effects of some drugs. Studies have found that the expression level of IGLC6 can be used as an indicator of the efficacy of drugs to treat certain immune diseases. For example, anti-rheumatic drugs (DM) can inhibit the expression of IGLC6, thereby improving the efficacy of treating rheumatoid arthritis. In addition, IGLC6 can also serve as a potential target for the treatment of certain inflammatory diseases.

The role of IGLC6 in the treatment of immune diseases

With the deepening of research, it has been discovered that IGLC6 has high value in the treatment of immune diseases. First, IGLC6 can be used as an indicator of the efficacy of drugs to treat certain immune diseases. For example, antirheumatic drugs can inhibit the expression of IGLC6, thereby improving the efficacy of treating rheumatoid arthritis. also,

Protein Name: Immunoglobulin Lambda Constant 6

Functions: Constant region of immunoglobulin light chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)

More Common Targets